

# Role of P-Glycoprotein in Drug Disposition

Therapeutic Drug Monitoring

22, 137-140

DOI: 10.1097/00007691-200002000-00029

Citation Report

#	ARTICLE	IF	CITATIONS
1	Desloratadine: A new, nonsedating, oral antihistamine. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 107, 751-762.	1.5	147
2	Pharmacokinetic Aspects of Treating Infections in the Intensive Care Unit. <i>Clinical Pharmacokinetics</i> , 2001, 40, 833-868.	1.6	123
3	Role of P-Glycoprotein and Organic Anion Transporting Polypeptides in Drug Absorption and Distribution. <i>Clinical Drug Investigation</i> , 2001, 21, 587-596.	1.1	15
4	The doseâ€“concentrationâ€“effect relationshipsâ€“the basis for TDM. A critical appraisal. <i>International Congress Series</i> , 2001, 1220, 117-123.	0.2	3
5	Pharmacogenomics: will it change the field of medicine?. <i>Clinica Chimica Acta</i> , 2001, 308, 1-8.	0.5	49
6	SEX AND ETHNICITY MAY CHIEFLY INFLUENCE THE INTERACTION OF FLUCONAZOLE WITH CALCINEURIN INHIBITORS <sup>12</sup> . <i>Transplantation</i> , 2001, 71, 1069-1075.	0.5	24
7	Factors Influencing the Prediction of Steady State Concentrations of Digoxin.. <i>Biological and Pharmaceutical Bulletin</i> , 2001, 24, 403-408.	0.6	16
8	Herb-Drug Interactions: Focus on Pharmacokinetics. <i>CNS Spectrums</i> , 2001, 6, 827-832.	0.7	22
9	Transport characteristics of peptides and peptidomimetics: II. Hydroxyethylamine bioisostere-containing peptidomimetics as substrates for the oligopeptide transporter and P-glycoprotein in the intestinal mucosa. <i>Chemical Biology and Drug Design</i> , 2001, 57, 361-373.	1.2	17
10	The use of transgenic mice in pharmacokinetic and pharmacodynamic studies. <i>Journal of Pharmaceutical Sciences</i> , 2001, 90, 422-435.	1.6	10
11	A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. <i>Pharmaceutical Research</i> , 2001, 18, 171-176.	1.7	73
12	MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. <i>Pharmaceutical Research</i> , 2001, 18, 1400-1404.	1.7	288
13	Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 69, 169-174.	2.3	628
14	MDR1 Genotype-Related Pharmacokinetics and Pharmacodynamics.. <i>Biological and Pharmaceutical Bulletin</i> , 2002, 25, 1391-1400.	0.6	167
15	Secretory Transport of Methylprednisolone Possibly Mediated by P-Glycoprotein in Caco-2 Cells.. <i>Biological and Pharmaceutical Bulletin</i> , 2002, 25, 393-396.	0.6	27
16	Influence of Different Chemicals on MDR-1 P-Glycoprotein Expression and Activity in the HK-2 Proximal Tubular Cell Line. <i>Toxicology and Applied Pharmacology</i> , 2002, 183, 83-91.	1.3	42
17	MDR1 up-regulated by apoptotic stimuli suppresses apoptotic signaling. <i>Pharmaceutical Research</i> , 2002, 19, 1323-1329.	1.7	40
18	Hepatic drug metabolism and transport in patients with kidney disease. <i>American Journal of Kidney Diseases</i> , 2003, 42, 906-925.	2.1	103

#	ARTICLE	IF	CITATIONS
19	Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats. Archives of Pharmacal Research, 2003, 26, 768-772.	2.7	198
20	Drug efflux transporters in the CNS. Advanced Drug Delivery Reviews, 2003, 55, 83-105.	6.6	273
21	Impact of solutol HS 15 on the pharmacokinetic behaviour of colchicine upon intravenous administration to male Wistar rats. Biopharmaceutics and Drug Disposition, 2003, 24, 173-181.	1.1	34
22	Oral antifungal drug interactions. Dermatologic Clinics, 2003, 21, 543-563.	1.0	9
23	Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics, 2003, 4, 397-410.	0.6	208
24	Dietary Effects on Drug Metabolism and Transport. Clinical Pharmacokinetics, 2003, 42, 1071-1088.	1.6	186
25	Principles and Clinical Application of Assessing Alterations in Renal Elimination Pathways. Clinical Pharmacokinetics, 2003, 42, 1193-1211.	1.6	76
27	ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut, 2003, 52, 1788-1795.	6.1	263
28	Hesperetin Glucuronide, a Photoprotective Agent Arising from Flavonoid Metabolism in Human Skin Fibroblasts. Photochemistry and Photobiology, 2003, 78, 256.	1.3	46
29	The Role of Absorption, Distribution, Metabolism, Excretion and Toxicity in Drug Discovery. Current Topics in Medicinal Chemistry, 2003, 3, 1125-1154.	1.0	226
31	Frequency Distribution of C3435T Mutation in Exon 26 of the MDR1 Gene in a Spanish Population. Therapeutic Drug Monitoring, 2003, 25, 107-111.	1.0	64
32	Polymorphism in the P-glycoprotein drug transporter MDR1 gene. Pharmacogenetics and Genomics, 2003, 13, 259-263.	5.7	178
33	Measurement of hepatic and intestinal CYP3A4 and PGP activity by combined po + iv [ <sup>14</sup> C]erythromycin breath and urine test. American Journal of Physiology - Renal Physiology, 2003, 285, G470-G482.	1.6	23
34	Effect of Aging on the Pharmacokinetics of Gastrointestinal Drugs. , 2003, 32, 28-39.		8
35	THE FATE OF XENOBIOTICS IN LIVING ORGANISMS. , 2003, , 501-515.		2
36	Pharmacokinetics of Baicalin in Rats and its Interactions with Cyclosporin A, Quinidine and SKF-525A: A Microdialysis Study. Planta Medica, 2004, 70, 1069-1074.	0.7	40
37	Pharmacogenetics of Drug Transporters and Its Impact on the Pharmacotherapy. Current Topics in Medicinal Chemistry, 2004, 4, 1383-1396.	1.0	87
38	Pharmacogenetics-Based New Therapeutic Concepts. Drug Metabolism Reviews, 2004, 36, 617-638.	1.5	32

#	ARTICLE	IF	CITATIONS
39	Differential Involvement of Multidrug Resistance-Associated Protein 1 and P-Glycoprotein in Tissue Distribution and Excretion of Grepafloxacin in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 310, 648-655.	1.3	49
40	P-glycoprotein drug transporter MDR1 gene polymorphism in renal transplant patients with and without gingival overgrowth. <i>Journal of Clinical Periodontology</i> , 2004, 31, 758-763.	2.3	34
41	Imidazole H3-antagonists: relationship between structure and ex vivo binding to rat brain H3-receptors. <i>European Journal of Pharmaceutical Sciences</i> , 2004, 23, 89-98.	1.9	13
42	Substrates and inhibitors of efflux proteins interfere with the MTT assay in cells and may lead to underestimation of drug toxicity. <i>European Journal of Pharmaceutical Sciences</i> , 2004, 23, 181-188.	1.9	97
43	Localisation of drug permeability along the rat small intestine, using markers of the paracellular, transcellular and some transporter routes. <i>European Journal of Pharmaceutical Sciences</i> , 2004, 23, 385-391.	1.9	46
44	Effect of cyclosporine A on the tissue distribution and pharmacokinetics of etoposide. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 153-60.	1.1	16
46	Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2004, 369, 69-77.	1.4	45
47	P-glycoprotein function in the elderly. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 97-102.	0.8	52
48	New oral drugs in older patients: a review of idarubicin in elderly patients. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 49, 153-163.	2.0	29
49	Spontaneous mitochondrial membrane potential change during apoptotic induction by quercetin in K562 and K562/adr cells. <i>Canadian Journal of Physiology and Pharmacology</i> , 2004, 82, 1084-1090.	0.7	27
50	The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour: does celecoxib enhance the anti-tumour activity of doxorubicin?. <i>Pharmacological Research</i> , 2004, 50, 487-498.	3.1	60
51	Pharmacokinetics and Pharmacodynamics of Intravenous Inotropic Agents. <i>Clinical Pharmacokinetics</i> , 2004, 43, 187-203.	1.6	69
52	The ABC Transporters MDR1 and MRP2: Multiple Functions in Disposition of Xenobiotics and Drug Resistance. <i>Drug Metabolism Reviews</i> , 2004, 36, 669-701.	1.5	114
53	Transport of somatostatin and substance P by human P-glycoprotein. <i>FEBS Letters</i> , 2004, 574, 55-61.	1.3	4
54	Effects of grapefruit juice on the multidrug transporter P-glycoprotein in the human proximal tubular cell line HK-2. <i>Life Sciences</i> , 2004, 76, 293-302.	2.0	56
55	Bioidentical hormone therapy: a review. <i>Menopause</i> , 2004, 11, 356-367.	0.8	96
56	Expression of Multidrug Resistance Proteins in Rat and Human Chronic Pancreatitis. <i>Pancreas</i> , 2004, 28, 45-52.	0.5	11
57	Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. <i>Blood</i> , 2004, 104, 1940-1951.	0.6	146

#	ARTICLE	IF	CITATIONS
59	MDR1 Genetic Polymorphisms and Comparison of MDR1 Haplotype Profiles in Korean and Vietnamese Populations. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 531-535.	1.0	36
60	Application of Two-Point Assay of Digoxin Serum Concentration in Studying Population Pharmacokinetics in Egyptian Pediatric Patients with Heart Failure: Does It Make Sense?. <i>American Journal of Therapeutics</i> , 2005, 12, 320-327.	0.5	2
61	P-glycoprotein expression induced by glucose depletion enhanced the chemosensitivity in human hepatocellular carcinoma cell-lines. <i>Cell Biology International</i> , 2005, 29, 269-275.	1.4	10
62	Development of a PCR-based diagnostic test detecting a nt230(del4) MDR1 mutation in dogs: verification in a moxidectin-sensitive Australian Shepherd. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2005, 28, 95-99.	0.6	46
63	Frequency of the nt230 (del4) MDR1 mutation in Collies and related dog breeds in Germany. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2005, 28, 545-551.	0.6	57
64	Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. <i>Journal of Controlled Release</i> , 2005, 103, 405-418.	4.8	543
65	Considerations in the Treatment of Dyslipidemia Associated With Chronic Kidney Failure and Renal Transplantation. <i>Preventive Cardiology</i> , 2005, 8, 244-249.	1.1	10
66	Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 389-394.	0.8	79
67	P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 55, 110-116.	1.1	30
68	Cancer pharmacogenomics: international trends. <i>International Journal of Clinical Oncology</i> , 2005, 10, 5-13.	1.0	25
70	Fluvastatin in the Treatment of Dyslipidemia Associated with Chronic Kidney Failure and Renal Transplantation. <i>Renal Failure</i> , 2005, 27, 259-273.	0.8	0
71	LOCALIZATION AND mRNA EXPRESSION OF CYP3A AND P-GLYCOPROTEIN IN HUMAN DUODENUM AS A FUNCTION OF AGE. <i>Drug Metabolism and Disposition</i> , 2005, 33, 1603-1607.	1.7	133
72	Improving Cancer Therapeutics by Molecular Profiling. <i>Current Drug Metabolism</i> , 2005, 6, 553-568.	0.7	4
73	Identification of the Hepatic Efflux Transporters of Organic Anions Using Double-Transfected Madin-Darby Canine Kidney II Cells Expressing Human Organic Anion-Transporting Polypeptide 1B1 (OATP1B1)/Multidrug Resistance-Associated Protein 2, OATP1B1/Multidrug Resistance 1, and OATP1B1/Breast Cancer Resistance Protein. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 314, 1059-1067.	1.3	189
74	Ontogeny of Renal P-glycoprotein Expression in Mice: Correlation with Digoxin Renal Clearance. <i>Pediatric Research</i> , 2005, 58, 1284-1289.	1.1	22
75	Doxorubicin loaded pH-sensitive micelle targeting acidic extracellular pH of human ovarian A2780 tumor in mice. <i>Journal of Drug Targeting</i> , 2005, 13, 391-397.	2.1	133
76	Fluvastatin in the Treatment of Dyslipidemia Associated with Chronic Kidney Failure and Renal Transplantation. <i>Renal Failure</i> , 2005, 27, 259-273.	0.8	6
77	The Role of P-Glycoprotein and Organic Anion-Transporting Polypeptides in Drug Interactions. <i>Drug Safety</i> , 2005, 28, 789-801.	1.4	71

#	ARTICLE	IF	CITATIONS
78	The ability to predict drug interactions mediated by active drug transport systems can help optimise pharmacotherapy. <i>Drugs and Therapy Perspectives</i> , 2006, 22, 22-26.	0.3	0
79	Pharmacokinetics and interactions of headache medications, part I: introduction, pharmacokinetics, metabolism and acute treatments. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2006, 2, 961-979.	1.5	10
80	Pharmacokinetics and Safety of Olmesartan Medoxomil in Combination with Glibenclamide in Healthy Volunteers. <i>Clinical and Experimental Hypertension</i> , 2006, 28, 631-643.	0.5	7
81	Enhancement of drug absorption by noncharged detergents through membrane and P-glycoprotein binding. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2006, 2, 733-752.	1.5	63
82	Induction of Human P-Glycoprotein in Caco-2 cells: Development of a Highly Sensitive Assay System for P-Glycoprotein-Mediated Drug Transport. <i>Drug Metabolism and Pharmacokinetics</i> , 2006, 21, 414-423.	1.1	44
83	The MDR1/ABCB1 Gene, a High-Impact Risk Factor for Cardiac Transplant Rejection. <i>Transplantation</i> , 2006, 82, 1677-1682.	0.5	24
84	In-vitro transport characteristics discriminate wild-type ABCB1 (MDR1) from ALA893SER and ALA893THR polymorphisms. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 855-861.	0.7	40
85	Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2006, 5, 3.	1.7	206
86	Modulation of P-glycoprotein activity by cannabinoid molecules in HK-2 renal cells. <i>British Journal of Pharmacology</i> , 2006, 148, 682-687.	2.7	25
87	Impact of inflammation on the duodenal mRNA expression of CYP3A and P-glycoprotein in children with Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 745-749.	0.9	49
88	Effect of benzo[a]pyrene on P-glycoprotein-mediated transport in Caco-2 cell monolayer. <i>Toxicology</i> , 2006, 223, 156-165.	2.0	18
89	Variability in Response to Cardiovascular Drugs. <i>Current Clinical Pharmacology</i> , 2006, 1, 35-46.	0.2	17
90	Independent and incremental prognostic value of endogenous ouabain in idiopathic dilated cardiomyopathy. <i>European Journal of Heart Failure</i> , 2006, 8, 179-186.	2.9	46
91	In Vivo Inhibition of Growth of Human Tumor Lines by Flavonoid Fractions From Cranberry Extract. <i>Nutrition and Cancer</i> , 2006, 56, 86-94.	0.9	75
92	Bioidentical estradiol gel for hormone therapy in menopause. <i>Expert Review of Obstetrics and Gynecology</i> , 2007, 2, 423-430.	0.4	1
93	Pharmacogenetics: where are we with respect to personalized medicine?. <i>Expert Opinion on Medical Diagnostics</i> , 2007, 1, 117-128.	1.6	0
94	Transport of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin by Human Organic Anion Transporter 3, Organic Anion Transporting Polypeptide 4C1, and Multidrug Resistance P-glycoprotein. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 321, 673-683.	1.3	158
95	Dose-Dependent Effects of the 3435 C>T Genotype of ABCB1 Gene on the Steady-State Plasma Concentration of Fluvoxamine in Psychiatric Patients. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 185-189.	1.0	45

#	ARTICLE	IF	CITATIONS
96	Effects of benzo(e)pyrene and benzo(a)pyrene on P-glycoprotein-mediated transport in Caco-2 cell monolayer: A comparative approach. <i>Toxicology in Vitro</i> , 2007, 21, 827-834.	1.1	16
97	Identifying P-Glycoprotein Substrates Using a Support Vector Machine Optimized by a Particle Swarm. <i>Journal of Chemical Information and Modeling</i> , 2007, 47, 1638-1647.	2.5	71
98	Genotype and Phenotype Relationship in Drug Metabolism. , 2007, , 81-100.		5
99	ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. <i>Pharmacogenomics Journal</i> , 2007, 7, 154-179.	0.9	247
100	Passive Permeability and Active Transport Models for the Prediction of Oral Absorption. , 2007, , 259-278.		8
101	Endothelial and Epithelial Cells: General Principles of Selective Vectorial Transport. , 2007, , 632-642.		0
102	Polymorphism of the human MDR1 gene in Siberian and Central Asian populations. <i>Molecular Biology</i> , 2007, 41, 894-900.	0.4	1
103	Hesperetin Glucuronide, a Photoprotective Agent Arising from Flavonoid Metabolism in Human Skin Fibroblasts. <i>Photochemistry and Photobiology</i> , 2003, 78, 256-261.	1.3	5
104	Immunocytochemical studies on the distribution pattern of daunomycin in rat gastrointestinal tract. <i>Histochemistry and Cell Biology</i> , 2007, 128, 285-290.	0.8	9
105	Microdosing Assessment to Evaluate Pharmacokinetics and Drug Metabolism in Rats Using Liquid Chromatography-Tandem Mass Spectrometry. <i>Pharmaceutical Research</i> , 2008, 25, 1572-1582.	1.7	44
106	Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 61, 365-376.	1.1	155
107	No association between MDR1 (ABCB1) 2677G>T and 3435C>T polymorphism and sporadic colorectal cancer among Bulgarian patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 317-322.	1.2	35
108	Effect of P-glycoprotein Expression Levels on the Concentration-Dependent Permeability of Drugs to the Cell Membrane. <i>Journal of Pharmaceutical Sciences</i> , 2008, 97, 553-565.	1.6	104
109	Evaluation of the pharmacokinetics of digoxin in healthy subjects receiving etoricoxib. <i>British Journal of Clinical Pharmacology</i> , 2008, 66, 811-817.	1.1	12
111	Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin. <i>Drug Metabolism and Disposition</i> , 2008, 36, 2014-2023.	1.7	322
112	Hepatic Uptake and Excretion of (S)-N-(2-((R)-3-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino)ethyl)-4-fluorobenzamide (YM758), a Novel If Channel Inhibitor, in Rats and Humans. <i>Drug Metabolism and Disposition</i> , 2008, 36, 1030-1038.	1.7	17
113	P-Glycoprotein Inhibitory Activity of Lipophilic Constituents of <i>Echinacea pallida</i> Roots in a Human Proximal Tubular Cell Line. <i>Planta Medica</i> , 2008, 74, 264-266.	0.7	28
114	Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 390-402.	0.7	50

#	ARTICLE	IF	CITATIONS
115	Altered nonrenal drug clearance in ESRD. <i>Current Opinion in Nephrology and Hypertension</i> , 2008, 17, 555-559.	1.0	61
116	No pharmacokinetic interaction between paliperidone extended-release tablets and trimethoprim in healthy subjects. <i>Human Psychopharmacology</i> , 2009, 24, 532-539.	0.7	27
117	Addition of TPGS to folate-conjugated polymer micelles for selective tumor targeting. <i>Journal of Biomedical Materials Research - Part A</i> , 2009, 91A, 505-518.	2.1	42
118	ABCB1 gene polymorphisms and haplotype analysis in colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2009, 24, 895-905.	1.0	45
119	Concentration-Dependent Effect of Naringin on Intestinal Absorption of $^{125}$ I-Adrenoceptor Antagonist Talinolol Mediated by P-Glycoprotein and Organic Anion Transporting Polypeptide (Oatp). <i>Pharmaceutical Research</i> , 2009, 26, 560-567.	1.7	86
120	Metabolism and Renal Elimination of Gaboxadol in Humans: Role of UDP-Glucuronosyltransferases and Transporters. <i>Pharmaceutical Research</i> , 2009, 26, 459-468.	1.7	18
121	Assessing drug distribution in tissues expressing P-glycoprotein using physiologically based pharmacokinetic modeling: identification of important model parameters through global sensitivity analysis. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2009, 36, 495-522.	0.8	11
122	In Vivo Evaluation of Doxorubicin-Loaded Polymeric Micelles Targeting Folate Receptors and Early Endosomal pH in Drug-Resistant Ovarian Cancer. <i>Molecular Pharmaceutics</i> , 2009, 6, 1353-1362.	2.3	166
123	Detergents as intrinsic P-glycoprotein substrates and inhibitors. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2009, 1788, 2335-2344.	1.4	58
124	Modern Pharmaceutics Volume 1. , 0, , .		12
125	Effect of P-glycoprotein inhibition on methadone analgesia and brain distribution in the rat. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 56, 367-374.	1.2	70
126	Effects of continuous exposure to digoxin on MDR1 function and expression in Caco-2 cells. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 55, 675-681.	1.2	14
127	ABCB1/MDR1 gene polymorphisms as a prognostic factor in colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2010, 25, 1167-1176.	1.0	44
128	MDR1-P-glycoprotein (ABCB1)-Mediated Disposition of Amyloid- $\beta$ Peptides: Implications for the Pathogenesis and Therapy of Alzheimer's Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 88, 441-443.	2.3	23
129	Histone Methyltransferase MLL1 Regulates MDR1 Transcription and Chemoresistance. <i>Cancer Research</i> , 2010, 70, 8726-8735.	0.4	59
130	Pharmacokinetic and Pharmacodynamic Implications of P-Glycoprotein Modulation. <i>Methods in Molecular Biology</i> , 2010, 596, 359-384.	0.4	22
131	P-glycoprotein expression and function are increased in an animal model of amyotrophic lateral sclerosis. <i>Neuroscience Letters</i> , 2010, 472, 166-170.	1.0	46
132	Multidrug resistance in oral squamous cell carcinoma: The role of vacuolar ATPases. <i>Cancer Letters</i> , 2010, 295, 135-143.	3.2	74



#	ARTICLE	IF	CITATIONS
133	In vivo evaluation of [123I]-4-(2-(bis(4-fluorophenyl)methoxy)ethyl)-1-(4-iodobenzyl)piperidine, an iodinated SPECT tracer for imaging the P-gp transporter. <i>Nuclear Medicine and Biology</i> , 2010, 37, 469-477.	0.3	8
134	ADME Evaluation in Drug Discovery. 10. Predictions of P-Glycoprotein Inhibitors Using Recursive Partitioning and Naive Bayesian Classification Techniques. <i>Molecular Pharmaceutics</i> , 2011, 8, 889-900.	2.3	148
135	Clinical Importance of OATP1B1 and OATP1B3 in Drug-Drug Interactions. <i>Drug Metabolism and Pharmacokinetics</i> , 2011, 26, 220-227.	1.1	101
136	Adverse effects of concentrated green tea extracts. <i>Molecular Nutrition and Food Research</i> , 2011, 55, 874-885.	1.5	74
137	Associations between variants in the ABCB1 (MDR1) gene and corticosteroid dependence in children with Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 2308-2317.	0.9	20
138	Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 1634-1638.	1.0	19
139	Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 1630-1633.	1.0	23
140	Adverse Drug Reactions and Drug-drug Interactions. , 2011, , 1569-1589.		2
141	Investigation of ABCB1 1236 and 2677 SNPs in patients with peptic ulcer. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 22-27.	0.6	4
142	Hemarthrosis in a Patient on Warfarin Receiving Ceftazidime: A Case Report and Brief Review of Cephalosporin Interactions with Warfarin. <i>Annals of Pharmacotherapy</i> , 2012, 46, e19-e19.	0.9	14
143	Inhibition of V-ATPase and Carbonic Anhydrases as Interference Strategy with Tumor Acidification Processes. <i>Current Pharmaceutical Design</i> , 2012, 18, 1407-1413.	0.9	16
144	Drug Disposition in Pathophysiological Conditions. <i>Current Drug Metabolism</i> , 2012, 13, 1327-1344.	0.7	70
145	Targeted polymeric magnetic nanoparticles for brain imaging. , 2012, , .		0
146	Variant genotypes of MDR1 C3435T increase the risk of leukemia: evidence from 10 case-control studies. <i>Leukemia and Lymphoma</i> , 2012, 53, 1183-1187.	0.6	11
147	Potential P-Glycoprotein-Mediated Drug-Drug Interactions of Antimalarial Agents in Caco-2 cells. <i>American Journal of Tropical Medicine and Hygiene</i> , 2012, 87, 64-69.	0.6	14
148	Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response. <i>Expert Review of Clinical Pharmacology</i> , 2012, 5, 69-89.	1.3	89
149	Gene-Wide Characterization of Common Quantitative Trait Loci for ABCB1 mRNA Expression in Normal Liver Tissues in the Chinese Population. <i>PLoS ONE</i> , 2012, 7, e46295.	1.1	11
150	Cerebral expression of drug transporters in epilepsy. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 919-929.	6.6	83

#	ARTICLE	IF	CITATIONS
151	Pharmacological rationale for the treatment of chronic urticaria with second-generation non-sedating antihistamines at higher than standard doses. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 9-18.	1.3	33
152	Studies on pharmacokinetic mechanism of phenytoin resistance in refractory epilepsy. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 3189-3195.	1.6	6
153	Association of a multidrug resistance 1 gene polymorphism and colorectal cancer in the Korean population. <i>Oriental Pharmacy and Experimental Medicine</i> , 2013, 13, 225-230.	1.2	2
154	Nanotechnology for Cancer Treatment: Possibilities and Limitations. , 2013, , 37-56.		8
155	Targeted drug delivery for cancer therapy. , 2013, , 31-56.		5
156	Suppression of intestinal polyp development in Apc Min/+ mice through inhibition of P-glycoprotein using verapamil. <i>European Journal of Cancer Prevention</i> , 2013, 22, 8-10.	0.6	6
157	ABCB1 single nucleotide polymorphisms (1236C>T, 2677G>T, and 3435C>T) do not affect transport activity of human P-glycoprotein. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 314-323.	0.7	26
158	The Role of Inter-segmental Differences in P-glycoprotein Expression and Activity along the Rat Small Intestine in Causing the Double-peak Phenomenon of Substrate Plasma Concentration. <i>Drug Metabolism and Pharmacokinetics</i> , 2013, 28, 98-103.	1.1	26
159	Phorbol 12-myristate 13-acetate inhibits P-glycoprotein-mediated efflux of digoxin in MDCKII-MDR1 and Caco-2 cell monolayer models. <i>Acta Pharmacologica Sinica</i> , 2014, 35, 283-291.	2.8	9
160	The role of drug transporters in the kidney: lessons from tenofovir. <i>Frontiers in Pharmacology</i> , 2014, 5, 248.	1.6	62
161	P-glycoprotein (P-gp)-mediated efflux limits intestinal absorption of the Hsp90 inhibitor SNX-2112 in rats. <i>Xenobiotica</i> , 2014, 44, 763-768.	0.5	10
162	Colorectal cancer susceptibility: apparent gender-related modulation by ABCB1 gene polymorphisms. <i>Journal of Biomedical Science</i> , 2014, 21, 89.	2.6	11
163	Elucidating the molecular mechanism for the intracellular trafficking and fate of block copolymer micelles and their components. <i>Biomaterials</i> , 2014, 35, 1347-1358.	5.7	25
164	Investigation of the mechanism involved in the As2O3-regulated decrease in MDR1 expression in leukemia cells. <i>Oncology Reports</i> , 2014, 31, 926-932.	1.2	5
165	ABCB1 C3435T polymorphism and the lipid-lowering response in hypercholesterolemic patients on statins: a meta-analysis. <i>Lipids in Health and Disease</i> , 2015, 14, 122.	1.2	29
166	ABCB1 C3435T polymorphism is associated with leukemia susceptibility: evidence from a meta-analysis. <i>OncoTargets and Therapy</i> , 2015, 8, 1009.	1.0	9
167	Selected hybrid natural products as tubulin modulators. <i>European Journal of Medicinal Chemistry</i> , 2015, 94, 497-508.	2.6	16
168	Icariin may benefit the mesenchymal stem cells of patients with steroid-associated osteonecrosis by ABCB1-promoter demethylation: a preliminary study. <i>Osteoporosis International</i> , 2015, 26, 187-197.	1.3	49

#	ARTICLE	IF	CITATIONS
169	Proton channels and exchangers in cancer. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2015, 1848, 2715-2726.	1.4	158
170	Effect of Knockout of Mdr1a and Mdr1b ABCB1 Genes on the Systemic Exposure of a Doxorubicin-Conjugated Block Copolymer in Mice. <i>Molecular Pharmaceutics</i> , 2015, 12, 3175-3183.	2.3	5
171	Unravelling the complex drug-drug interactions of the cardiovascular drugs, verapamil and digoxin, with P-glycoprotein. <i>Bioscience Reports</i> , 2016, 36, .	1.1	34
172	Direct in vivo evidence on the mechanism by which nanoparticles facilitate the absorption of a water insoluble, P-gp substrate. <i>International Journal of Pharmaceutics</i> , 2016, 514, 121-132.	2.6	11
173	Design, synthesis, and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitors - Part 3. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 3716-3726.	1.4	8
174	Design, synthesis, and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitors - Part 2. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 3207-3217.	1.4	4
175	Elevated International Normalized Ratio values in a patient receiving warfarin and ceftaroline. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 56-59.	0.5	6
176	Excretion of a Highly Lipophilic Phenolic Antioxidant from Rats. <i>Pharmaceutical Chemistry Journal</i> , 2017, 51, 340-342.	0.3	2
177	Methadone as a -Tumor Therapeutic-against Cancer. <i>Frontiers in Pharmacology</i> , 2017, 8, 733.	1.6	13
178	Multifunctional micelle delivery system for overcoming multidrug resistance of doxorubicin. <i>Journal of Drug Targeting</i> , 2018, 26, 289-295.	2.1	20
180	The conformation and dynamics of P-glycoprotein in a lipid bilayer investigated by atomic force microscopy. <i>Biochemical Pharmacology</i> , 2018, 156, 302-311.	2.0	22
181	Pharmacogenomics and Personalized Medicine in the Treatment of Human Diseases. , 2018, , 731-743.		3
182	In Vitro to In Vivo Extrapolation of Metabolic Clearance for UGT Substrates Using Short-Term Suspension and Long-Term Co-cultured Human Hepatocytes. <i>AAPS Journal</i> , 2020, 22, 131.	2.2	18
183	Beverage-Drug Interaction: Effects of Green Tea Beverage Consumption on Atorvastatin Metabolism and Membrane Transporters in the Small Intestine and Liver of Rats. <i>Membranes</i> , 2020, 10, 233.	1.4	6
184	Effect of Common Excipients on Intestinal Drug Absorption in Wistar Rats. <i>Molecular Pharmaceutics</i> , 2020, 17, 2310-2318.	2.3	8
185	Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug-Drug Interaction Studies. <i>Clinical Pharmacokinetics</i> , 2020, 59, 699-714.	1.6	150
186	In-silico approach for designing novel urea/thiourea and schiff base of quinazolinone derivatives of molecular docking H+/K+-ATPase inhibitors. <i>Results in Chemistry</i> , 2021, 3, 100186.	0.9	1
189	Introduction to Drug-Drug Interactions. , 2018, , 1-13.		1

#	ARTICLE	IF	CITATIONS
190	Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 259-63.	5.7	72
191	Principles of Drug Absorption. <i>Drugs and the Pharmaceutical Sciences</i> , 2002, , .	0.1	3
192	Possible association of ABCB1:c.3435T>C polymorphism with high-density-lipoprotein-cholesterol response to statin treatment - a pilot study.. <i>Bosnian Journal of Basic Medical Sciences</i> , 2014, 14, 144-149.	0.6	15
193	The Impact of Opioid Analgesics and the Pharmacogenomics of ABCB1 in Opioid Dependence and Pharmacotherapies: A Short Review. <i>Open Pain Journal</i> , 2020, 13, 7-21.	0.4	7
194	Allele Frequency of Carbamazepine Major Efflux Transporter Encoding Gene ABCB1 C3435T among Javanese-Indonesian Population. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2020, 8, 406-413.	0.1	3
195	Colorectal cancers and chlorinated water. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 402.	0.8	9
196	Therapeutic use of amiodarone and attention to its side effects. <i>Japanese Journal of Electrocardiology</i> , 2002, 22, 77-83.	0.0	0
198	Pharmacological aspects of nephrotoxicity. , 2003, , 657-666.		0
199	Interaction of herbs with other medicines. , 2003, , 171-186.		0
200	Bodipy-FL-Verapamil: A Fluorescent Probe for the Study of Multidrug Resistance Proteins. <i>Analytical Cellular Pathology</i> , 2004, 26, 3-11.	0.7	6
203	Special Considerations in Research. , 2007, , 275-350.		0
204	Co-administration of Fexofenadine Reduces Serum Digoxin Concentration in Patient Undergoing Hemodialysis. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , 2008, 34, 252-255.	0.0	0
205	Pharmacogenomics and Personalized Medicine in the Treatment of Human Diseases. , 2009, , 613-622.		0
206	Drug Resistance in Epilepsy and Status Epilepticus. , 2010, , 61-81.		0
207	V-ATPase Inhibitors in Cancer Treatment and Their Implication in Multidrug Resistance in Oral Squamous Cell Carcinoma. , 0, , .		0
208	THE INFLUENCE OF EXPERIMENTAL SUBACUTE HYPOBARIC HYPOXIA ON P-GLYCOPROTEIN FUNCTIONAL ACTIVITY. I P Pavlov <i>Russian Medical Biological Herald</i> , 2013, 21, 60.	0.2	0
209	Colorectal cancer susceptibility: apparent gender-related modulation by. <i>Journal of Biomedical Science</i> , 2014, 21, 89.	2.6	5
210	Personalized Medicine for the Treatment of Human Cancer. , 2017, , 843-855.		0

#	ARTICLE	IF	CITATIONS
211	THE RELATIONSHIP BETWEEN CLINICO-PATHOLOGICAL PROPERTIES AND P-GLYCOPROTEIN EXPRESSION IN HIPPOCAMPAL SCLEROSIS AMONG PATIENTS WITH MESIAL TEMPORAL LOBE EPILEPSY WHO UNDERGO SELECTIVE AMYGDALOHIPPOCAMPECTOMY OPERATION. <i>Noropsikiyatri Arsivi</i> , 2018, 57, 204-209.	0.2	0
212	Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P-glycoprotein-cytochrome P450 3A4 dual substrates. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1485-1496.	1.3	12
213	<i>Pharmakogenetik und Pharmakogenomik.</i> , 2008, , 314-331.		0
214	Dietary Phytoestrogens and Their Metabolites as Epigenetic Modulators with Impact on Human Health. <i>Antioxidants</i> , 2021, 10, 1893.	2.2	22
215	In silico, ADMET and Docking Analysis for the Compounds of Chloroform Extract of <i>Tinospora cardifolia</i> (Wild.) Identified by GC-MS and Spectral Analysis for Antidiabetic and Anti-Inflammatory Activity. <i>Asian Journal of Chemistry</i> , 2022, 34, 342-354.	0.1	1
216	Prediction of CYP-mediated silybin A-losartan pharmacokinetic interactions using physiological based pharmacokinetic modeling. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2022, 49, 311-323.	0.8	5
217	OAT, OATP, and MRP Drug Transporters and the Remote Sensing and Signaling Theory. <i>Annual Review of Pharmacology and Toxicology</i> , 2023, 63, 637-660.	4.2	15
218	<i>Nanotechnology for the treatment of cancer: progress and challenges.</i> , 2023, , 285-307.		1
219	Association of the 1236C>T variant of the multidrug resistance 1 gene with esophageal squamous cell carcinoma development and prognosis. , 2022, , 201137.		0
220	Pharmaceutical polymers and P-glycoprotein: Current trends and possible outcomes in drug delivery. <i>Materials Today Communications</i> , 2023, 34, 105318.	0.9	7
221	An investigation of binding interactions of tumor-targeted peptide conjugated polyphenols with the kinase domain of ephrin B4 and B2 receptors. <i>Molecular Diversity</i> , 0, , .	2.1	1
222	Potential drug candidates as P-glycoprotein inhibitors to reverse multidrug resistance in cancer: an in silico drug discovery study. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 13977-13992.	2.0	4
223	Reduced P-glycoprotein recognition of a radioiodine-labeled phosphonium cation by stilbenylation for mitochondrial membrane potential based-imaging. <i>Bioorganic and Medicinal Chemistry</i> , 2023, 84, 117260.	1.4	1
233	Elucidating the Inhibition Mechanism of FDA-Approved Drugs on P-glycoprotein (P-gp) Transporter by Molecular Docking Simulation. <i>Algorithms for Intelligent Systems</i> , 2023, , 221-229.	0.5	1